In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
201 News Items found
a lab coat hangs in an MSK lab
MSK Research Highlights, March 20, 2026

New MSK research discovers a new approach that could prevent chemotherapy-related leukemia; shows how monoclonal antibodies can turn neutrophils into cancer killers; helps develop sensitive CAR T cells that target CD70 antigen to destroy cancer cells; and uses single-cell studies to yield new clues about a rare, aggressive pediatric sarcoma.
MSK Study Suggests Cancer Metastasis Is Wound Healing Gone Wrong

Scientists at the Sloan Kettering Institute have discovered that the ability of cancers to metastasize to other organs is dependent upon their ability to co-opt natural wound-healing pathways. In a literal sense, metastasis is wound healing gone wrong. These findings provide a novel framework for thinking about metastasis and how to treat it.
Physician-scientist Nai-Kong Cheung
Caging the Beast: MSK Researchers Design a New Radiation Treatment More Destructive to Cancer Cells

Learn about the work of Nai-Kong Cheung and other MSK scientists who have learned more about how to deliver stronger treatment with less toxicity.
Participants in Cycle for Survival
Treating Rare Cancers

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.
Maureen Sideris is seen smiling with her sister Marion.
Using Only Immunotherapy Successfully Treats Several Cancers With MMRd Mutation, Improves Quality of Life

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation, or chemotherapy.
a lab coat hangs in an MSK lab
MSK Research Highlights, November 6, 2024

New MSK research marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of artificial intelligence (AI); identifies two enzymes vital for maintaining brain health; uncovers how changes to “helper” proteins drive cancer cell survival; develops a new model for investigating lung cancer metastasis; and uses AI to improve outcome predictions in sarcoma.
Computational biologist Barry Taylor
Finding
Whether a BRCA Mutation Leads to Cancer Depends on Context, Study Finds

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.
MSK medical oncologist Alexander Drilon
Feature
First Targeted Cancer Drug Approved Based on Mutation Rather than Tumor Type

Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.
Dr. Michael Overholtzer
Feature
17 Gerstner Sloan Kettering Students Will Graduate in 2023

Seventeen scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 17, 2023, as part of Memorial Sloan Kettering’s 44th annual academic convocation.
ContactTracing graphic
New Research Shows How Cancer Rewires a Key Immune Pathway To Spread

A collaboration between MSK and Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, and shows how cancer can selfishly hijack a normally helpful immune pathway.